Tryp Therapeutics to Participate in Healthcare Conferences in January 2022
Tryp Therapeutics (CSE: TRYP, OTCQB: TRYPF) announced its participation in the upcoming H.C. Wainwright Bioconnect Conference and Biotech Showcase, scheduled for January 10-12, 2022. CEO Greg McKee will present updates on the company's psilocybin-based compounds aimed at chronic pain and eating disorders. The H.C. Wainwright event will be available on-demand from January 10, while the Biotech Showcase presentation occurs on January 11. Registered attendees can access pre-recorded sessions and replays on Tryp's website.
- None.
- None.
SAN DIEGO, Jan. 5, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present next week at the H.C. Wainwright Bioconnect Conference and the Biotech Showcase.
The events will be held virtually on January 10-12, 2022. Greg McKee, Chairman and CEO of Tryp, will provide an overview of the company and updates on Tryp's chronic pain and eating disorder programs.
H.C. Wainwright Bioconnect Conference
When: Available on-demand from January 10 at 7:00 a.m. ET
Registration: Available here
Biotech Showcase
When: Tuesday, January 11 at 6:30 p.m. ET
Registration: Available here
This year, all corporate presentations will be pre-recorded and available on-demand for registered attendees. Replays of the presentations will be available afterward on the Events section of Tryp's website.
About Tryp Therapeutics
Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs. Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and binge eating disorder, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information, please visit www.tryptherapeutics.com.
Investor Inquiries:
Joseph Green
Edison Group
investors@tryptherapeutics.com
Media Inquiries:
Abby Berger
KCSA Strategic Communications
TRYP@KCSA.com
1-833-811-8797
Forward-Looking Information
Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans," "targets," "expects" or "does not expect," "is expected," "an opportunity exists," "is positioned," "estimates," "intends," "assumes," "anticipates" or "does not anticipate" or "believes," or variations of such words and phrases or state that certain actions, events or results "may," "could," "would," "might," "will" or "will be taken," "occur" or "be achieved." In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events.
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the "Risk Factors" section of Tryp's final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View original content:https://www.prnewswire.com/news-releases/tryp-therapeutics-to-participate-in-healthcare-conferences-in-january-2022-301454087.html
SOURCE Tryp Therapeutics
FAQ
What are the dates for Tryp Therapeutics' upcoming presentations?
Who will present on behalf of Tryp Therapeutics?
What topics will Tryp Therapeutics cover in their presentations?
How can I register for the H.C. Wainwright Bioconnect Conference?
When will the presentations be available for on-demand viewing?
What is the significance of the Phase 2a clinical trials announced by Tryp Therapeutics?
